Physician profile
Olivia G Tack
NPI 1255371514
$1,702.91
in general payments reported to CMS, 2019-2025
15 companies · $218 in 2025
The $218 reported for 2025 was more than what 76% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.66 · 2020: $15.24 · 2021: $11.45 · 2022: $522 · 2023: $348 · 2024: $492 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $737.30 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $216.83 | 2022-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Tris Pharma INC | $199.08 | 2019-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $133.66 | 2019-2024 | |
| Pfizer INC. | $107.38 | 2019-2025 | |
| Sanofi Pasteur INC. | $63.72 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.89 | 2022 | |
| Collegium Pharmaceutical, INC. | $45.51 | 2025 | Jornay Pm |
| Seqirus USA INC | $33.62 | 2024-2025 | Flucelvax, Fluad |
| Astrazeneca Pharmaceuticals LP | $29.62 | 2024 | Flumist Quadrivalent |
| Rhodes Pharmaceuticals L.P. | $18.54 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.46 | 2024 | Qelbree |
| Shire North American Group INC | $17.28 | 2019 | |
| Opko Pharmaceuticals, LLC | $16.57 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Tack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.